Pfizer and BioNTech have begun a clinical trial for their Omicron-specific COVID-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

NEW YORK (WABC) -- We're learning more about the FDA's decision to further delay the COVID-19 vaccine that Pfizer is testing for children under age 5. This youngest group is the only age group not yet ...

Pfizer Inc. and BioNTech SE have announced that initial lab studies show a third dose of their Covid-19 vaccine neutralizes the Omicron variant. These results come as great news amid fears of a new ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

In "sobering news," omicron can evade the protection initial vaccines give, but boosters increase efficacy and better protect against the newest variant of concern, Dr. Anthony Fauci said Sunday. The ...

The FDA has approved a new COVID-19 vaccine formula targeting Omicron variants, but access to the vaccine is limited to those over 65 and individuals with certain preexisting medical conditions.

If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently. Moderna and Pfizer working on a bivalent vaccine that ...

The new updated COVID-19 vaccines for 2025-2026 will be available in the fall. Here are answers to some of the most common questions about the vaccine.